Month: April 2024

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

Written by Customer Service on April 1, 2024. Posted in Earnings Releases And Operating Results.

Establishes Full Year 2024 Revenue Guidance of $112 Million – $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on which we generated organic growth of 15% compared to the prior year,” said Sean Browne, President and CEO of Xtant Medical. “Additionally, we successfully integrated three separate businesses that are integral to our growth platform. From a profitability perspective, we increased our annual gross margin by 540 basis...

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

Written by Customer Service on April 1, 2024. Posted in Earnings Releases And Operating Results.

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights. “Despite OLINVYK’s differentiated profile, the hospital environment continues to be challenging. Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve...

Rakovina Therapeutics To Host Informational Webinar on April 3, 2024

Written by Customer Service on April 1, 2024. Posted in Public Companies.

Announces Capital Markets Advisory Agreement VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, will be hosting an informational webinar on Wednesday, April 3, 2024. The Rakovina leadership team and members of the scientific team will host the conference call to provide additional information about the company’s recent announcement regarding its collaboration with the Deep Docking AI platform and other industry insights. Conference Call Details:Date:Time:Link: April 3, 2024 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)https://events.irlabs.ca/rkv_eventRakovina...

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

Written by Customer Service on April 1, 2024. Posted in Public Companies.

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties. For more information, please refer to the announcement on the Viatris corporate website at https://newsroom.viatris.com/. About Ocuphire Pharma Ocuphire Pharma, Inc. is a clinical-stage...

Gilat Awarded Over $13M in Additional Orders from Satellite Operators for its World Leading SkyEdge IV and SkyEdge II-c Platforms

Written by Customer Service on April 1, 2024. Posted in Public Companies.

SkyEdge platforms are key enablers of in-flight connectivity, maritime mobility, cellular backhaul, and fixed data services globally PETAH TIKVA, Israel, April 01, 2024 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that the Company was awarded over $13M cumulative orders from multiple satellite operators to expand their global SATCOM networks utilizing Gilat’s SkyEdge IV multi-orbit, multi-service capabilities and leveraging its backward compatibility with SkyEdge II-c modems. These activities represent continuing orders resulting from the strategic partnerships forged with the selection of Gilat’s SkyEdge platforms by key satellite operators. SkyEdge platforms play a pivotal role in enabling in-flight connectivity,...

20 EH/s expansion fully funded

Written by Customer Service on April 1, 2024. Posted in Public Companies.

20 EH/s expansion fully funded 460MW of next-generation data centers Commencement of quarterly reporting SYDNEY, Australia, April 01, 2024 (GLOBE NEWSWIRE) — IREN (Iris Energy Limited) (NASDAQ: IREN) (together with its subsidiaries, “IREN” or “the Company”), a leading next-generation data center business powering the future of Bitcoin, AI and beyond, today provided a business update.2024 expansion, now fully funded$301m cash, no debt 460MW of data centers and 20 EH/s of Bitcoin mining in 2024 Expansion fully funded, following completion of a targeted ATM equity raising programIREN to commence quarterly reporting immediatelyStarting from the quarter ending March 31, 2024Next-generation data centers460MW of data center capacity in 2024, with land portfolio and executed connection agreements for 2,160MW...

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Written by Customer Service on April 1, 2024. Posted in Earnings Releases And Operating Results.

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challenging economic conditions during 2023 in the biotech sector and beyond, the Akari team advanced our Phase 3 and pre-clinical development programs and paved the way for a merger that, upon closing, will expand our pipeline and open the door to new potential growth and value creation opportunities,” said Rachelle Jacques, Akari President and CEO. “We believe we are building strong momentum and we’re excited about the possibilities that exist for our combined company.” Company Highlights Akari announced the company has reached a definitive...

Nxu, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on April 1, 2024. Posted in Earnings Releases And Operating Results.

MESA, Ariz., April 01, 2024 (GLOBE NEWSWIRE) — Nxu, Inc. (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company developing and manufacturing innovative EV charging and energy storage solutions, today announced financial results for the year ended Dec. 31, 2023. Nxu’s full year 2023 financial results and management commentary can be found by accessing the Company’s shareholder letter on the Investor Relations page of the Company’s website. “Reflecting on 2023, it emerges as a transformative chapter in Nxu’s history,” noted Nxu Founder, Chairman, and CEO Mark Hanchett. “The strides we took in developing our public charging units and Quartzsite charging facility set the stage for a successful 2024 and beyond. As we envision a future where charging infrastructure rivals that of traditional gas stations, where...

Old National Announces Completion of Merger with CapStar

Written by Customer Service on April 1, 2024. Posted in Mergers And Acquisitions.

EVANSVILLE, Ind., April 01, 2024 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – Old National Bancorp (“Old National”) today announced the closing of its previously-announced merger with Nashville-based CapStar Financial Holdings, Inc. (“CapStar”), the holding company for CapStar Bank, as of April 1. “This partnership is an incredible cultural fit and a natural extension of our growth strategy that allows us to introduce our client- and community-centered approach to banking to several strong, vibrant Southeastern communities,” said Old National Chairman and CEO Jim Ryan. “We are excited to have reached this important milestone and to officially welcome CapStar clients and team members to the Old National family.” After closing of the merger, Old National has approximately $52 billion of assets and $29 billion of assets under management (on...

Enservco Corporation Reports 2023 Fourth Quarter and Full Year Financial Results

Written by Customer Service on April 1, 2024. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2023 HighlightsRevenue flat overall with a completions services revenue increase offset by an expected production services revenue decrease from Q4 of 2022 Gross profit improves 14% General and administrative expenses down 2% Net loss increased to $1.9 million from $1.7 million, with the increase related to $0.5 million write down of goodwill in Q4 2023 Positive Adjusted EBITDA versus an Adjusted EBITDA loss in Q4 of 2022Full Year 2023 HighlightsRevenue up 2% compared to 2022 Gross profit improves 61% General and administrative expenses down 9% Net loss increased to $8.5 million from $5.6 million, due primarily to the write down of goodwill and the 2022 net loss including a $4.3 million non-cash gain on debt extinguishment Adjusted EBITDA loss improves 46%LONGMONT, Colo., April 01, 2024 (GLOBE NEWSWIRE) —...

Month: April 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals